IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by Rhumbline Advisers

Rhumbline Advisers decreased its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 3.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 175,970 shares of the company’s stock after selling 6,931 shares during the period. Rhumbline Advisers’ holdings in IDEXX Laboratories were worth $72,753,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in the company. Adell Harriman & Carpenter Inc. acquired a new position in IDEXX Laboratories during the fourth quarter worth approximately $413,000. V Square Quantitative Management LLC increased its position in IDEXX Laboratories by 6.2% during the fourth quarter. V Square Quantitative Management LLC now owns 2,076 shares of the company’s stock worth $858,000 after buying an additional 121 shares during the period. CFC Planning Co LLC acquired a new position in shares of IDEXX Laboratories in the fourth quarter valued at approximately $487,000. Vontobel Holding Ltd. increased its holdings in shares of IDEXX Laboratories by 90.1% in the fourth quarter. Vontobel Holding Ltd. now owns 418,563 shares of the company’s stock valued at $173,051,000 after purchasing an additional 198,404 shares during the period. Finally, Asset Management One Co. Ltd. increased its holdings in shares of IDEXX Laboratories by 6.1% in the fourth quarter. Asset Management One Co. Ltd. now owns 52,844 shares of the company’s stock valued at $21,927,000 after purchasing an additional 3,057 shares during the period. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Stock Down 3.3 %

IDEXX Laboratories stock opened at $444.53 on Monday. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 1.03. IDEXX Laboratories, Inc. has a 1-year low of $398.50 and a 1-year high of $583.39. The company has a market cap of $36.40 billion, a PE ratio of 41.66, a price-to-earnings-growth ratio of 3.47 and a beta of 1.37. The stock’s 50 day moving average price is $430.95 and its 200 day moving average price is $452.96.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the company. StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, February 5th. Bank of America boosted their target price on IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a report on Tuesday, February 4th. Leerink Partnrs raised IDEXX Laboratories to a “strong-buy” rating in a report on Monday, December 2nd. Piper Sandler boosted their target price on IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a report on Monday, February 10th. Finally, Barclays boosted their target price on IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a report on Tuesday, February 4th. Four equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $533.75.

Insiders Place Their Bets

In other IDEXX Laboratories news, EVP George Fennell sold 9,986 shares of the business’s stock in a transaction on Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the sale, the executive vice president now directly owns 8,176 shares in the company, valued at approximately $3,781,645.28. The trade was a 54.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director M Anne Szostak sold 3,000 shares of the business’s stock in a transaction on Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the sale, the director now owns 3,061 shares in the company, valued at approximately $1,426,242.34. The trade was a 49.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 13,330 shares of company stock worth $6,161,276. 2.11% of the stock is owned by corporate insiders.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.